PATENT CLAIM ANALYSIS

Application Number: 15878644
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-06
Patent Classification: ["424", "139100"]

Abstract:
Disclosed is a monoclonal antibody binding to an ITM2A protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as Ewing's sarcoma, T cell leukemia, T cell lymphoma, acute myeloid leukemia, B cell tumor, and multiple myeloma. The present invention also provides a pharmaceutical composition, a cell growth inhibitor, and an anticancer agent containing the antibody as an active ingredient, and a method for treating cancer, a method for predicting the efficacy of cancer treatment, and a method for determining the presence of cancer in a test subject using the antibody.

Claim (Index 60):
The method according to  claim 48 , wherein the antibody is a bispecific antibody.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 86.0
- Lexical Diversity: 1.81967
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14173424', '12742892', '14008447', '12444916', '13138014']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7816881983224192
- 35 USC 102 Novelty (BERT): 0.5384313866149039
- Combined Prediction Score: 0.7573625171516677
- Mean Citation Score: 369.773784
- Max Citation Score: 386.27008
- Similarity Product: 265.6649073433304

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test